The ability to alter proteins to refine control over binding affinity and specificity can create tailored therapeutics with reduced side effects, highly sensitive diagnostic tools, efficient ...
Heterogeneity in prevalence estimates identified across studies and regions indicates that more research is required to draw stronger conclusions about the scale of OCSEA. However, the findings of ...
Asaf Nurick, Fionic’s co-founder and former CTO, along with core members of his AI R&D team, have joined ODDITY and will focus on solving high impact missions via AI, harnessing proven methods of ...